Market News & Trends
Genesis Drug Discovery & Development Expands Preclinical Contract Research Portfolio With Acquisition
Genesis Drug Discovery & Development (GD3), the contract research organization (CRO) of Genesis Biotechnology Group (GBG), recently announced that it has expanded its drug development services through…
Owlstone Medical Announces a Novel Approach to Breath-Based Testing
Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine, recently announced the development of an innovative alternative…
Akari Therapeutics’ Nomacopan Demonstrates Positive Early Safety & Efficacy
Akari Therapeutics, Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated,…
Developing Microfluidic Routes to Effective Nanoparticle Drug Delivery Systems
A Dolomite Microfluidics’ set-up is helping researchers in the University of Manchester’s Division of Pharmacy and Optometry to enhance drug delivery. Dr Annalisa Tirella explained:…
Array BioPharma Acquisition Will Accelerate Pfizer’s Position as a Major Player in Colorectal Cancer
Following the news that Pfizer has agreed to acquire Array BioPharma in a deal worth approximately $11.4 billion, Tajekesa Chapman, PhD, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on the potential of this buy-out on the treatment of colorectal cancers.
IVERIC bio Enters Strategic Manufacturing Relationship With Catalent's Paragon Gene Therapy
IVERIC bio, Inc. and Catalent Biologics recently announced they have entered into an agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) vector for IVERIC bio’s gene therapy product candidates.
Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study
Progenics Pharmaceuticals, Inc. recently announced that the first patient has been dosed in the company’s Phase 2 clinical study evaluating I-131 1095 radiotherapy in combination…
Innovate Biopharmaceuticals Announces Start of First Phase 3 Clinical Trial
Innovate Biopharmaceuticals, Inc. recently announced the start of the first Phase 3 clinical trial in celiac disease. Innovate expects to provide further updates as screening…
Deciphera Pharmaceuticals and Zai Lab Limited Announce Exclusive License Agreement
Deciphera Pharmaceuticals, Inc. and Zai Lab Ltd. recently announced an exclusive license agreement to advance the development and commercialization of ripretinib in Greater China (mainland…
InflaRx Treats First Patient in Phase 2a Clinical Trial
InflaRx N.V. recently announced the treatment of the first patient in a Phase 2a clinical trial evaluating the company’s lead product candidate, IFX-1, in Pyoderma…
Oncologie Closes $80-Million Financing for Clinical-Stage Pipeline
Oncologie recently announced it has closed an $80M Series B financing. Existing investors, led by Nan Fung Life Sciences and Pivotal BioVentures China, are joined…
CytoDyn & FDA Will Meet to Potentially Finalize Protocol for Pivotal Monotherapy Trial
CytoDyn Inc. recently announced the US FDA has requested an in-person meeting to discuss and potentially finalize the company’s recently submitted protocol for a pivotal…
Ligand Subsidiary Vernalis & PhoreMost Limited Announce Collaboration for Novel Oncology Target
Ligand Pharmaceuticals Incorporated and PhoreMost Limited recently announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target.
Designing a CMC Strategy for Accelerated Development of Biotherapeutics
As the pipeline of biologic drugs intended to treat complex disease expands, the typical timeline for drug development seems to be shortening more frequently and with more intensity……..
DRGT Completes a Pivotal Phase I Trial; Results Confirm 6X Faster Attainment of Maximum Plasma Levels
Druggability Technologies Holdings (DRGT) recently announced results from a pharmacokinetic study of their novel formulation of celecoxib (DRGT-46), which achieves faster time to maximum plasma concentration (Tmax) compared to traditional celecoxib capsules.
Insilico Launches Comprehensive Portfolio of Predictive Digital Twins for Cell Culture Process Development
In close alignment with customer needs Insilico Biotechnology AG has developed a modular suite of Digital Twins that cover key steps during bioprocess development.
Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million
Biogen recently announced it has completed its acquisition of Nightstar Therapeutics, a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.
Enable Injections Enters Strategic Partnership With Sanofi
Enable Injections, Inc. recently announced it has entered into a multi-product development agreement with Sanofi S.A.
Aptar Acquires Nanopharm & Gateway Analytical
AptarGroup, Inc. recently announced it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million.
ASLAN Pharmaceuticals Completes Phase 1 Study
ASLAN Pharmaceuticals recently announced the successful completion of its single ascending dose (SAD) study testing the first-in-class therapeutic antibody ASLAN004 in healthy volunteers, and the…
